Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting

On September 27, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported details of an abstract accepted for poster presentation at the upcoming Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, which will be held in San Diego, November 3-5, 2023 (Press release, Actinium Pharmaceuticals, SEP 27, 2023, View Source [SID1234635439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details of the SITC (Free SITC Whitepaper) poster presentation:

Abstract Title: Preclinical evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate targeting myeloid-derived suppressor cells
Abstract Number: 1166
Session: November 4, 9:00 AM – 8:30 PM PT, Exhibit Halls A and B1

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!